NGR 6538 EXAM 2 GUIDE QUESTIONS AND
CORRECT DETAILED ANSWERS (VERIFIED
ANSWERS) | ALREADY GRADED A+ | NEW
UPDATE 2025
dopamine pathways - ANSWER Nigrostriatal
Mesolimbic
Mesocortical
Tuberoinfundibular
dopamine theory - ANSWER excess of dopamine implicated in schizophrenia
mesolimbic pathway in schizophrenia - ANSWER positive symptoms, too much
dopamine
mesocortical pathway in schizophrenia - ANSWER negative and cognitive
symptoms, too little dopamine
Nigrostriatal pathway - ANSWER Hyperactivity of dopamine in this pathway
leads to movement disorders
Antipsychotics decrease dopamine
tuberofundibular pathway - ANSWER Dopamine inhibits prolactin via this
pathway. Antipsychotics decrease dopamine, increasing prolactin, causing
gynecomastia
, Antipsychotics with the lowest metabolic risk - ANSWER Aripiprazole and
Lurasidone
Antipsychotics with the highest metabolic risk - ANSWER Quetiapine and
olanzapine
Antipsychotic that increases QT prolongation - ANSWER Geodon
Side effects of clozapine - ANSWER Agranulocytosis (neutropenia) and seizures
Clozapine monitoring - ANSWER CBC weekly for 6 months
then CBC every 2 weeks for 6 months
then CBC monthly
Clozapine adjunct - ANSWER Prophylactic antiepileptics recommended
2nd generation antipsychotics recommended for bipolar depression - ANSWER
Lurasidone, olanzapine/fluoxetine, quetiapine
Olanzapine LAI adverse reaction - ANSWER Delirium
Part of the brain that dopamine affects - ANSWER midbrain
CORRECT DETAILED ANSWERS (VERIFIED
ANSWERS) | ALREADY GRADED A+ | NEW
UPDATE 2025
dopamine pathways - ANSWER Nigrostriatal
Mesolimbic
Mesocortical
Tuberoinfundibular
dopamine theory - ANSWER excess of dopamine implicated in schizophrenia
mesolimbic pathway in schizophrenia - ANSWER positive symptoms, too much
dopamine
mesocortical pathway in schizophrenia - ANSWER negative and cognitive
symptoms, too little dopamine
Nigrostriatal pathway - ANSWER Hyperactivity of dopamine in this pathway
leads to movement disorders
Antipsychotics decrease dopamine
tuberofundibular pathway - ANSWER Dopamine inhibits prolactin via this
pathway. Antipsychotics decrease dopamine, increasing prolactin, causing
gynecomastia
, Antipsychotics with the lowest metabolic risk - ANSWER Aripiprazole and
Lurasidone
Antipsychotics with the highest metabolic risk - ANSWER Quetiapine and
olanzapine
Antipsychotic that increases QT prolongation - ANSWER Geodon
Side effects of clozapine - ANSWER Agranulocytosis (neutropenia) and seizures
Clozapine monitoring - ANSWER CBC weekly for 6 months
then CBC every 2 weeks for 6 months
then CBC monthly
Clozapine adjunct - ANSWER Prophylactic antiepileptics recommended
2nd generation antipsychotics recommended for bipolar depression - ANSWER
Lurasidone, olanzapine/fluoxetine, quetiapine
Olanzapine LAI adverse reaction - ANSWER Delirium
Part of the brain that dopamine affects - ANSWER midbrain
